Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis

Checkpoint inhibitor-related pneumonitis (CIP) is a common fatal immune-related adverse events of PD-1/PD-L1 inhibitors. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of precise and effective diagnostic techniques often leads to underdiagnosis and misdiagnosis. The investigators conducted a prospective clinical study to evaluate the effectiveness of ¹H-nuclear magnetic resonance (NMR)-based lipoprotein and metabolite analysis in diagnosing checkpoint inhibitor-related pneumonitis (CIP), aiming to improve its early diagnosis rate.

NCT Number	NCT07340892
Lead Sponsor	Zhou Chengzhi
Conditions	Checkpoint Inhibitor-related Pneumonitis
Enrollment	60 participants
Start Date	2026-01-10
Primary Completion	2027-01-10 (estimated)
Study Completion	2028-01-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-04